Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PT Phapros, Tbk (PEHA.JK)
Jakarta, ID
PT Phapros, Tbk is a prominent Indonesian company operating within the pharmaceutical and healthcare sectors. Its operations are broadly categorized into four key divisions: Over-the-Counter (OTC) products, Ethical drugs, Generic drug manufacturing, and Toll Manufacturing services. The company's OTC offerings feature well-known brands such as Antimo Anak, Livron B Plek, Noza, Hemorogard, and Bioron. In addition to supplying generic medications to government institutions and hospitals, PT Phapros also serves as a contract manufacturer for other pharmaceutical companies and provides various medical devices. Established in 1954 with its headquarters located in Jakarta, Indonesia, the company further extends its market reach by exporting products internationally. PT Phapros, Tbk functions as a subsidiary under the umbrella of PT Kimia Farma (Persero) Tbk.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.72% | -5.52% | -8.05% | -6.80% | -14.38% | -8.05% | -19.41% | -59.41% | -77.90% | -84.78% | -84.78% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+26.3% ★ Q1'26: +10.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+109.8% ★ Q1'26: +126.6% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+6.6% Q1'26: +11.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+9.2% Q1'26: +5.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+5.1% Q1'26: +3.1% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×5.19× Q1'26: 7.19× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|
| Revenue |
1.01T
est: 1.31T (-22.5%)
|
744.69B
est: 1.62T (-54.0%)
|
940.88B
est: 1.99T (-52.7%)
|
| EBITDA |
120.77B
est: 59.62B (+102.6%)
|
-282.91B
est: 50.94B (-655.4%)
|
136.09B
est: 62.59B (+117.4%)
|
| EBIT |
71.95B
est: 2.04B (+3,422.0%)
|
-297.85B
est: -19.96B (-1,392.5%)
|
86.74B
est: -24.52B (+453.8%)
|
| Net Income |
5.96B
est: 73.00B (-91.8%)
|
-285.07B
est: 90.89B (-413.6%)
|
28.03B
est: 107.18B (-73.8%)
|
| SGA |
232.09B
est: 337.34B (-31.2%)
|
282.61B
est: 462.86B (-38.9%)
|
359.57B
est: 568.70B (-36.8%)
|
| EPS |
7.09
est: 86.90 (-91.8%)
|
-339.37
est: 108.20 (-413.7%)
|
33.37
est: 127.60 (-73.8%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Diah Istantri | Head of Risk Management Department | — | male |
| Erfan Rio Prananto | General Manager of Accounting | — | male |
| Ferdinand Troedu | Director of Finance, Risk Management & Human Resources | — | male |
| Ida Rahmi Kurniasih | Acting Official President Director & Production Director | — | female |
| Intan Abdams Katoppo | President Director | — | female |
| Maraja Jeson Siregar | Director of Marketing & Director | — | male |
| Riza Effendi | Head of Internal Control Unit | — | male |
| Yudhi Rangkuti | Finance, Risk Management & Human Capital Director and Director | — | male |
| Zahmilia Akbar | Corporate Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PEHA.JK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
